Latest news with #Dyrupeg
Business Standard
5 hours ago
- Business
- Business Standard
Aurobindo Pharma gets UK MHRA approval for neutropenia treatment drug Dyrupeg
Aurobindo Pharma said that wholly owned step-down subsidiary CuraTeQ Biologics s.r.o. has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg. Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a 'biosimilar medicine'; this means that Dyrupeg is highly similar to another biological medicine (the 'reference medicine) that is already authorised in the area of the regulatory agency. Dyrupeg is intended for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQs third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025. Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The companys consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24. The scrip advanced 0.84% to currently trade at Rs 1113.25 on the BSE.
Business Standard
7 hours ago
- Business
- Business Standard
Stock Alert: PTC Inds, Mastek, Aurobindo Pharma, JB Chemicals, Hindalco Inds
Securities in F&O Ban: Titgarh Rail Systems shares are banned from F&O trading on 25 June 2025. Stocks to Watch: PTC Industries subsidiary, Aerolloy Technologies announced the memorandum of understanding (MoU) with Safran Aircraft Engines to develop cooperation on the manufacturing of components and materials for military aircraft engines. Masteks chief financial officer, Raghavendra Jha has submitted his resignation from the services. Aurobindo Pharmas wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has obtained marketing authorization from the UKs Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg. JB Chemicals & Pharmaceuticals has received approval from United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Amitriptyline Hydrochloride tablets. Rashtriya Chemicals & Fertilizers (RCF)s board approved raising non convertible debentures (NCDs) worth Rs 300 crore on private placement basis. Hindalco Industries has announced the acquisition of 100% equity stake in US-based AluChem Companies for an enterprise value of $125 million. The acquisition will be carried out through Aditya Holdings LLC, a stepdown wholly owned subsidiary of Hindalco.
Time of India
11 hours ago
- Business
- Time of India
Aurobindo Pharma shares in focus after subsidiary CuraTeQ gets UK nod for Dyrupeg
Aurobindo Pharma shares will be in focus on Wednesday after its wholly-owned step-down subsidiary, CuraTeQ Biologics s.r.o., received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg , a biosimilar of pegylated filgrastim . "CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version," according to a stock exchange filing. This is CuraTeQ's third biosimilar approval from the UK regulator, following the authorisations of Bevqolva in December 2024 and Zefylti in May 2025. Dyrupeg is used to reduce the risk of infection in cancer patients undergoing chemotherapy and had earlier received marketing approval from the European Commission in April 2025. Also Read: Coforge among 10 high-conviction stock ideas that can rally up to 52% Aurobindo Pharma Q4 earnings For the March quarter, Aurobindo Pharma reported an 11% year-on-year rise in consolidated revenue to Rs 8,382.1 crore, broadly in line with Street expectations. The growth was mainly driven by a 13.5% YoY increase in US formulation sales and a 17.2% jump in European formulations. Net profit for the quarter stood at Rs 902.8 crore, marginally lower than Rs 907.4 crore in the same quarter last year. EBITDA rose 7.1% YoY to Rs 1,792 crore, with an EBITDA margin of 21.38%, slightly down from the previous year. Also Read: 11 Nifty mid & smallcap stocks that can rally 40-90% over the next 12 months Aurobindo Pharma shares price target According to Trendlyne, the average target price for Aurobindo Pharma shares is Rs 1,403, indicating a potential 27% upside from current levels. Among 27 analysts covering the stock, the consensus rating is 'Buy'. On Tuesday, the stock closed 0.4% higher at Rs 1,104 on the BSE. While it has declined 18% year-to-date, it has more than doubled—rising 110%—over the past three years. The company's current market capitalisation is around Rs 64,120 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Business Upturn
12 hours ago
- Business
- Business Upturn
Top stocks in focus on June 25: JB Chemicals, Infosys, PTC Industries, HAL, IRCTC, and more
By Aman Shukla Published on June 25, 2025, 08:21 IST The Indian stock market is set for an eventful session on Wednesday, June 25, with several companies announcing fresh developments that could draw investor attention. Here's a look at key corporate news and updates that may influence stock movement: JB Chemicals received US FDA approval for its generic Amitriptyline Hydrochloride tablets, expanding its regulated market portfolio. Infosys announced a strategic tie-up with Zoetis, aimed at boosting IT and digital operations using AI and automation solutions. Aurobindo Pharma's subsidiary CuraTeQ Biologics received marketing approval in the UK for Dyrupeg, a biosimilar of pegylated filgrastim. Servotech Renewable won a ~16 MW rooftop solar project from Madhya Pradesh Urja Vikas Nigam Ltd, strengthening its clean energy pipeline. PTC Industries' subsidiary Aerolloy Technologies signed an MoU with Safran Aircraft Engines to develop a domestic manufacturing ecosystem for military aircraft engines. Bajel Projects secured a large substation order in India valued between Rs 1–2 billion. Glenmark Pharmaceuticals launched lung cancer drug Tevimbra in the Indian market. IndiGo reported a slight rise in market share for May, climbing to 64.6% from 64.1% the previous month. KFin Technologies reappointed Vishwanathan Mavila Nair as Chairman for a one-year term starting October 1, 2025. IRCTC is likely to be in focus as Indian Railways prepares for a nationwide fare hike across all passenger categories starting July 1. HAL confirmed that the Indian Air Force will receive at least six Tejas fighter jets by March 2026. Bondada Engineering landed a Rs 836 crore order for battery energy storage systems from Tamil Nadu Green Energy Corporation, to be executed over 12 years. Ashok Leyland announced plans to expand its commercial vehicle footprint by adding 50 new outlets in North India. Hindalco said its US-based subsidiary, Aditya Holdings LLC, will acquire AluChem Companies Inc., a specialty alumina producer, for $125 million. India Glycols reported record-high sales of its alcoholic beverage brand 'Bunty Bubbly' for FY24–25. Supreme Infrastructure secured a Rs 4.5 billion turnkey project in Mumbai, taking its total order book to Rs 17.25 billion. Rites received a letter of intent for a Rs 28.5 crore infrastructure project from Gujarat Urban Development Company. CWD Ltd announced an initial order worth Rs 8 crore from a leading digital services provider. Several companies reported key management changes, including India Gelatine, Kabra Extrusion, Rathi Steel, Vibhor Steel, and National Plastic, all involving resignations of company secretaries or senior officers. Enviro Infra received a GST department notice over tax dues totaling Rs 8.4 crore for the period FY19–FY24. Vodafone Idea clarified that it has not received any formal communication from the government regarding potential relief on its outstanding dues. CIE Automotive will invest Rs 2.6 crore to acquire up to 29% in AMP Energy C&I Thirty Two Private Ltd. Petronet LNG, Ador Welding, and Automobile Corporation of Goa announced record dates for their final dividends. India Cements, Mahindra & Mahindra, Bharat Bijlee, and HSCL reported credit rating updates and investment activities that may influence their respective valuations. Lloyd Metals completed the acquisition of a 26.82% stake in HR Godavari Private Limited for Rs 17.4 crore. Mastek said CFO Raghavendra Jha will step down on July 11, 2025. Kaynes Technology closed its Qualified Institutional Placement, issuing 28.73 lakh shares at Rs 5,569.50 per share. BLS E-Services announced it will acquire customer service points of SBI and HDFC Bank through its subsidiary under a deal worth around Rs 6.5 crore. Union Bank of India revoked the appointment of Pankaj Dwivedi as Executive Director with immediate effect. Dredging Corporation of India was removed from the Short-Term Additional Surveillance Measure (ASM) list. Several companies are trading ex-date today, including Elitecon International (stock split), Quest Capital, Aegis Logistics, and Automobile Corporation of Goa (dividends). Infibeam Avenues is scheduled to open its rights issue tomorrow, June 26. CG Power received a tax notice from the Income Tax Department proposing an additional liability of Rs 1,194.54 crore following a draft assessment order. Timex Group promoters are looking to offload a 15% stake in the India unit via an Offer for Sale at Rs 175 per share. Tata Motors may see global headwinds as Jaguar Land Rover faces potential exposure of up to £1.6 billion due to proposed US tariffs. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash HALInfosysIRCTCJB ChemicalsPTC IndustriesStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
India Today
12 hours ago
- Business
- India Today
Stocks to watch on June 25: Infosys, Union Bank, RITES, Aurobindo Pharma
Stock market investors are expected to keep a close watch on several key companies during Tuesday's trade, after a volatile session on Tuesday as it tracked the developments in the Middle East. The benchmark indices showed sharp ups and downs before closing with small a detailed look at the stocks that may move today based on company announcements and market has announced a strategic partnership with Zoetis, the world's leading animal health company. The collaboration will help Zoetis improve its IT operations by using advanced artificial intelligence (AI) solutions and automation tools. The move is aimed at improving efficiency and supporting Zoetis' growth through better digital BANK OF INDIAThe government has cancelled the appointment of Pankaj Dwivedi as Executive Director of Union Bank. Dwivedi, who was earlier a general manager at Punjab & Sind Bank, was appointed in March 2023 for a three-year term. His removal may raise questions about management changes at the public sector GROUP INDIAPromoter Timex Group Luxury Watches BV, Netherlands, will sell up to 15% stake in Timex Group India through an Offer for Sale (OFS). The base offer is 7.5% or around 75.71 lakh shares. The OFS opens for non-retail investors on June 25 and for retail investors on June 26. The floor price has been set at Rs 175 per PHARMAAurobindo Pharma's subsidiary CuraTeQ Biologics has received approval from the UK's drug regulator MHRA for its biosimilar medicine, Dyrupeg. This drug is used to treat cancer patients suffering from neutropenia, a condition that lowers white blood cell count. The product had earlier received authorisation in the European Union in April is the third biosimilar from CuraTeQ to get approval from MHRA, after Bevqolva in December 2024 and Zefylti in May MOTORSTata Motors said that its production process has not yet been impacted by China's restrictions on exports of rare-earth magnets. These magnets are important for electric vehicles. The company is actively looking at other options for sourcing and developing new technologies to reduce dependency on has received a Letter of Intent worth Rs 28.5 crore from Gujarat Urban Development Company. The company will work as a third-party inspection agency for various water supply and sewage treatment projects in the state under Amrut 2.0 and other INDUSTRIESPTC Industries' subsidiary, Aerolloy Technologies, has signed a Memorandum of Understanding (MoU) with Safran Aircraft Engines. The deal is for producing parts and materials used in military aircraft engines. This move is likely to boost defence manufacturing under the 'Make in India' TECHNOLOGIESThe board of KFin Technologies has approved the re-appointment of Vishwanathan Mavila Nair as Non-Executive Director and Chairperson of the company. His second term will begin from October 1, 2025, and will last for one TECHNOLOGY INDIAKaynes Technology has raised Rs 1,600 crore by allotting 28.72 lakh shares to qualified institutional buyers at an issue price of Rs 5,569.50 per share. The fundraise was part of a Qualified Institutions Placement (QIP) that closed on June 24. Some of the investors include Motilal Oswal Mutual Fund, Nomura Funds, HSBC Mutual Fund, Kotak Mahindra AMC, and HDFC Life Insurance WELLNESSZydus Wellness' board has approved the voluntary closure of its subsidiary Naturell (India) Private Limited. The decision is part of a plan to simplify the company's structure and bring operational efficiency by merging Naturell with the main entity.- Ends advertisement
